- Concanamycin A
-
- $293.00 / 100μg
-
2026-04-27
- CAS:80890-47-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| Product Name: | CONCANAMYCIN A | | Synonyms: | CONCANAMYCIN A;CONCANAMYCIN A, STREPTOMYCES SP;concanamycin A from streptomyces species;A661-I;Antibiotic A661I;Antibiotic S-45A;S-45A;(3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)-18-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[[4-O-(Aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyloxacyclooctadeca-3,5,13,15-tetraen-2-one | | CAS: | 80890-47-7 | | MF: | C46H75NO14 | | MW: | 866.09 | | EINECS: | 620-709-4 | | Product Categories: | | | Mol File: | 80890-47-7.mol |  |
| | CONCANAMYCIN A Chemical Properties |
| Melting point | 179-180℃ (dichloromethane ethanol ) | | Boiling point | 966.4±65.0 °C(Predicted) | | density | 1.20±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | Soluble in DMSO | | form | Lyophilized solid | | pka | 12.46±0.70(Predicted) | | color | White | | BRN | 3560277 | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. | | InChIKey | DJZCTUVALDDONK-NZJBBTFCNA-N | | SMILES | CCC1C(O)C(C)C\C(C)=C\C=C\C(OC)C(OC(=O)\C(OC)=C\C(C)=C\C(C)C1O)C(C)C(O)C(C)[C@]2(O)C[C@@H](O[C@H]3C[C@@H](O)[C@H](OC(N)=O)[C@@H](C)O3)[C@H](C)C(O2)\C=C\C |
| Hazard Codes | T+ | | Risk Statements | 26/27/28-36 | | Safety Statements | 26-36/37/39-45 | | RIDADR | UN 3462 6.1/PG 2 | | WGK Germany | 3 | | RTECS | CB9732000 | | F | 10-21 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 2941900000 | | Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | | Hazard Classifications | Acute Tox. 1 Inhalation
Acute Tox. 2 Dermal
Acute Tox. 2 Oral
Eye Irrit. 2 |
| | CONCANAMYCIN A Usage And Synthesis |
| Description | Concanamycin A (80890-47-7) is a potent and specific inhibitor of the vacuolar (V-type) H+-ATPase which can induce apoptotic cell death in various cell lines.1,2Inhibits cell surface expression of virus envelope glycoproteins.3Dramatically increases the rate of extracellular vesicle release from a variety of cell types.4Inhibits autophagy by blocking lysosomal acidification.5 | | Uses | Concanamycin A has been used:
- as a lysosomal inhibitor in young and old fibroblasts
- as a vacuolar-type H+-ATPase inhibitor in presynaptic vesicles
- as a lysosomal acidification blocker in HepG2 hepatocytes cells
| | Uses | Concanamycin A is the major analogue of the concanamycin complex produced by Streptomyces sp.. It has been shown to act as a potent and specific vacuolar-ATPase inhibitor. Concanamycin A inhibits the acidification of organelles and blocks cell surface expression of viral envelope glycoproteins without affecting their synthesis. It also interferes with intracellular protein trafficking and inhibits perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Concanamycins are structurally related to the bafilomycins. | | Definition | ChEBI: A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group. | | General Description | Chemical structure: macrolide | | Biological Activity | Specific inhibitor of V-type (vacuolar) H + -ATPase that displays > 2000-fold selectivity over other H + -ATPases (IC 50 values are 9.2, > 20000, > 20000 and > 20000 nM for yeast V-type, F-type, P-type H + -ATPases and porcine P-type Na + ,K + -ATPase respectively). Blocks cell surface expression of virus envelope glycoproteins without affecting synthesis and exhibits cytotoxicity in several cell lines. | | Biochem/physiol Actions | Concanamycin A (ConA) inhibits acidification of organelles and perforin-mediated cytotoxicity. It is a vacuolar-type v-ATPase inhibitor. ConA possesses antiprotozoal and antineoplastic properties. It mediates inhibition of the negative factor (Nef) protein of the human immunodeficiency virus. | | storage | Store at -20°C | | Background | Concanamycin A is a macrolide antibiotic derived from S. diastatochromogenes that is effective against several fungi and yeasts. Concanamycin A is an exceptionally potent and specific inhibitor of the ATP-driven proton pumps known as vacuolar type H+-ATPases. V-ATPases acidify intracellular compartments and translocate protons across the plasma membrane. Intracellular V-ATPases play an important role in endocytosis and intracellular membrane trafficking, while plasma membrane V-ATPases are important in processes such as urinary acidification and bone resorption. Treatment of murine cells with Concanamycin A results in apoptosis, evidenced by an increase in fragmented DNA and the number of apoptotic cells with hypodiploid DNA. Concanamycin A induced production of nitric oxide and decreased cell growth and survival in mouse leukemic monocyte cells. Concanamycin A reversed the downregulation of cell surface MHC-I by the HIV-encoded accessory protein Nef, suggesting a possible therapeutic role of Concanamycin A in enhancing the immune-mediated clearance of HIV-infected cells. | | References | [1] NISHIHARA T. Specific Inhibitors of Vacuolar Type H+-ATPases Induce Apoptotic Cell Death[J]. Biochemical and biophysical research communications, 1995, 212 1: Pages 255-262. DOI:10.1006/bbrc.1995.1964
[2] JANGJA HONG. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells.[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 319 2: 672-681. DOI:10.1124/jpet.106.109280
[3] M MUROI. Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus.[J]. Cell structure and function, 1993, 18 3: 139-149. DOI:10.1247/csf.18.139
[4] ANIL G CASHIKAR P I H. A cell-based assay for CD63-containing extracellular vesicles.[J]. ACS Applied Bio Materials, 2019: e0220007. DOI:10.1371/journal.pone.0220007
[5] SYLWIA GRADZKA. Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes.[J]. Cell Death & Disease, 2018: 529. DOI:10.1038/s41419-018-0508-y |
| | CONCANAMYCIN A Preparation Products And Raw materials |
|